Intrarectal quinine
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cerebral Malaria
Conditions
Cerebral Malaria
Trial Timeline
Sep 1, 2003 → Jan 1, 2004
NCT ID
NCT00124267About Intrarectal quinine
Intrarectal quinine is a phase 3 stage product being developed by Sanofi for Cerebral Malaria. The current trial status is unknown. This product is registered under clinical trial identifier NCT00124267. Target conditions include Cerebral Malaria.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00124267 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Cerebral Malaria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mouse nerve growth factor | Sun Pharmaceutical | Approved | 85 |
| Edaravone Dexborneol + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Oral Glycopyrrolate Liquid | Shionogi | Phase 3 | 77 |
| recombinant human erythropoietin alfa + 0.9% NaCl | Johnson & Johnson | Phase 2/3 | 65 |
| UDI-001 | Rohto Pharmaceutical | Phase 1/2 | 41 |
| NXY-059 | AstraZeneca | Phase 3 | 77 |
| NXY-059 | AstraZeneca | Phase 2 | 52 |
| Rosuvastatin | AstraZeneca | Approved | 85 |
| NXY-059 | AstraZeneca | Phase 3 | 77 |
| Comparator: Placebo + Comparator: MK0724 | Merck | Phase 2 | 52 |
| Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mg | Merck | Phase 2 | 52 |
| Recombinant Factor VIIa + Biological/Vaccine: Placebo | Novo Nordisk | Phase 3 | 76 |
| Recombinant Activated Factor VII (rFVIIa) + Placebo | Novo Nordisk | Phase 3 | 76 |
| Ponezumab | Pfizer | Phase 2 | 51 |
| PF-05230907 | Pfizer | Phase 1 | 32 |
| Azithromycin + Pyrimethamine + Leucovorin calcium | Pfizer | Phase 1 | 32 |
| clopidogrel (SR25990C) | Sanofi | Approved | 84 |
| Piracetam | UCB | Approved | 82 |
| Placebo + ALN-APP | Alnylam Pharmaceuticals | Phase 2 | 49 |
| CN-105 | Tiantan Bio | Phase 2 | 49 |